Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells
Abstract: Decitabine (5-aza-2′-deoxycytidine) is a DNA methyltransferase inhibitor and an archetypal epigenetic drug for the therapy of myeloid leukemias. The mode of action of decitabine strictly depends on the incorporation of the drug into DNA. However, DNA incorporation and ensuing genotoxic effects of decitabine have not yet been investigated in human cancer cell lines or in models related to the approved indication of the drug. Here we describe a robust assay for the quantitative determination of decitabine incorporation rates into DNA from human cancer cells. Using a panel of human myeloid leukemia cell lines we show appreciable amounts of decitabine incorporation that closely correlated with cellular drug uptake. Decitabine incorporation was also detectable in primary cells from myeloid leukemia patients, indicating that the assay is suitable for biomarker analyses to predict drug responses in patients. Finally, we also used next-generation sequencing to comprehensively analyze the effects of decitabine incorporation on the DNA sequence level. Interestingly, this approach failed to reveal significant changes in the rates of point mutations and genome rearrangements in myeloid leukemia cell lines. These results indicate that standard rates of decitabine incorporation are not genotoxic in myeloid leukemia cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Nucleic acids research. - 42, 19 (2014) , e152-, ISSN: 1362-4962
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2019
- Urheber
-
Öz, Aliye Simin
Raddatz, Günter
Rius, Maria
Blagitko-Dorfs, Nadja
Lübbert, Michael
Maercker, Christian
Lyko, Frank
- DOI
-
10.1093/nar/gku775
- URN
-
urn:nbn:de:bsz:25-freidok-1218021
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Öz, Aliye Simin
- Raddatz, Günter
- Rius, Maria
- Blagitko-Dorfs, Nadja
- Lübbert, Michael
- Maercker, Christian
- Lyko, Frank
- Universität
Entstanden
- 2019
Ähnliche Objekte (12)
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Absence of early platelet increment in healthy mice during decitabine treatment
Absence of early platelet increment in healthy mice during decitabine treatment
Non-small cell lung cancer cell vulnerability to decitabine and retinoic acid combinatorial treatment
Epigenetic therapy of cancer : preclinical models and treatment approaches
Charakterisierung der antileukämischen Aktivität von drei Hydroxamat-Histondesacetylase-Inhibitoren
DNA-Methylierungssignaturen bei älteren Patienten mit akuter myeloischer Leukämie
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Absence of early platelet increment in healthy mice during decitabine treatment
Absence of early platelet increment in healthy mice during decitabine treatment
Non-small cell lung cancer cell vulnerability to decitabine and retinoic acid combinatorial treatment
Epigenetic therapy of cancer : preclinical models and treatment approaches
Charakterisierung der antileukämischen Aktivität von drei Hydroxamat-Histondesacetylase-Inhibitoren
DNA-Methylierungssignaturen bei älteren Patienten mit akuter myeloischer Leukämie
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Absence of early platelet increment in healthy mice during decitabine treatment
Absence of early platelet increment in healthy mice during decitabine treatment
Non-small cell lung cancer cell vulnerability to decitabine and retinoic acid combinatorial treatment
Epigenetic therapy of cancer : preclinical models and treatment approaches
Charakterisierung der antileukämischen Aktivität von drei Hydroxamat-Histondesacetylase-Inhibitoren
DNA-Methylierungssignaturen bei älteren Patienten mit akuter myeloischer Leukämie